CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

First patient dosed in Artelo’s Phase II DREAM study for glaucoma

Phase 2ART27.13Positive
AI Analysis

Summary

Artelo Biosciences has dosed the first patient in the Phase II DREAM study evaluating ART27.13 for glaucoma and ocular hypertension treatment.

Clinical Trial Data

Phase

Phase 2

Importance:4/10
Sentiment:
0.30
Phase 2glaucomaocular hypertensiontrial initiation
Related Companies

Read the original article

Published by Clinical Trials Arena on August 11, 2026 10:00 AM

Read Original